VACCINEX
Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows them to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. It is based in Rochester, New York.
VACCINEX
Industry:
Biotechnology Clinical Trials Health Care Oncology
Founded:
1997-01-01
Address:
Rochester, New York, United States
Country:
United States
Website Url:
http://www.vaccinex.com
Total Employee:
11+
Status:
Active
Contact:
585-271-2700
Email Addresses:
[email protected]
Total Funding:
80.7 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SPF Google Tag Manager WordPress Google Analytics SSL By Default Global Site Tag IPv6
Similar Organizations
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Integral Molecular
Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies
Fore Biotherapeutics
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Oncora Medical
Oncora Medical is a digital health company integrating big data and machine learning into radiation oncology.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Maurice Zauderer
Maurice Zauderer investment in Post-IPO Equity - Vaccinex
Jacob Frieberg
Jacob Frieberg investment in Post-IPO Equity - Vaccinex
Albert Friedberg
Albert Friedberg investment in Post-IPO Equity - Vaccinex
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Vaccinex
Official Site Inspections
http://www.vaccinex.com Semrush global rank: 4 M Semrush visits lastest month: 2.72 K
- Host name: vps125413.inmotionhosting.com
- IP address: 199.250.207.85
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Vaccinex"
Corporate Overview - Vaccinex
Aug 14, 2024 Vaccinex Inc. 1895 Mount Hope Avenue, Rochester, NY 14620 P: 585 271 2700 F: 585 271 2765 [email protected]See details»
Vaccinex | Science in the service of medicine
Aug 14, 2024 Vaccinex is studying pepinemab in clinical trials of patients with Huntington’s and Alzheimer’s disease, and is exploring the potential to treat other neurological disorders. In …See details»
Vaccinex - Crunchbase Company Profile & Funding
Organization. Vaccinex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Vaccinex may be growing as indicated by a recent public offering where the company …See details»
Vaccinex - LinkedIn
Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the …See details»
Contact - Vaccinex
General Contact Information. Vaccinex Inc. 1895 Mount Hope Avenue Rochester, NY 14620. Ph: 585-271-2700 Fx: 585-271-2765. [email protected] Media RequestsSee details»
Vaccinex Inc company information, history, management and …
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The …See details»
Vaccinex Company Profile 2024: Stock Performance & Earnings
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The …See details»
Vaccinex Inc (VCNX-Q) Profile - The Globe and Mail
See the company profile for Vaccinex Inc (VCNX-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Vaccinex, Inc. (VCNX) Company Information - Simply Wall St
Vaccinex, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day. …See details»
Vaccinex, Inc. Company Profile | Rochester, NY | Competitors ...
Find company research, competitor information, contact details & financial data for Vaccinex, Inc. of Rochester, NY. Get the latest business insights from Dun & Bradstreet.See details»
Vaccinex Inc, VCNX:NAQ profile - FT.com - Financial Times
Nov 25, 2024 Year on year Vaccinex Inc grew revenues 107.27% from 275.00k to 570.00k while net income improved from a loss of 19.82m to a smaller loss of 20.25m. View all financials. …See details»
Vaccinex Management - Simply Wall St
Vaccinex's CEO is Maurice Zauderer, appointed in Apr 2001, has a tenure of 23.67 years. total yearly compensation is $430.28K, comprised of 95.7% salary and 4.3% bonuses, including …See details»
Vaccinex Inc, VCNX:PKC summary - FT.com - Financial Times
3 days ago Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and …See details»
Vaccinex Faces Nasdaq Delisting Amid Financial ... - Yahoo Finance
Dec 17, 2024 According to Nasdaq Listing Rule 5550(b), Vaccinex was warned on December 16, 2024, that its shares will be delisted for non-compliance with its equity requirement of $2.5 …See details»
Vaccinex - Huntington's Disease Society of America
Company Overview Vaccinex, Inc. (Nasdaq: VCNX) is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key …See details»
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet ...
Dec 17, 2024 Vaccinex announces Nasdaq delisting due to non-compliance with equity standards; trading shifts to OTC Markets. Quiver AI Summary. Vaccinex, Inc., a clinical-stage …See details»
Organization: Vaccinex - Cbonds.com
Organization: Vaccinex Organization name. Vaccinex, Inc. Country name. USA Country of registration. USA. Industry. Pharmaceutical Preparation and Biotechnology. Bond debt - …See details»
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical …See details»
Vaccinex, Inc. Careers and Employment | Indeed.com
Find out what works well at Vaccinex, Inc. from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and …See details»
Vaccinex receives delisting notification from Nasdaq
Dec 17, 2024 Try Now>>See Insiders’ Hot Stocks on TipRanks >> Read More on VCNX:Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last yearVaccinex provides update on …See details»